EN DE
Watch Odyssey Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes.
Data-driven stock valuation

Odyssey Therapeutics, Inc. (ODTX) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of Odyssey Therapeutics, Inc. stock $11.46, price $20.00, that is 42.7% below the price, quality 34 out of 100. Rating: strongly overvalued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

OT Odyssey Therapeutics, Inc. logo Thin data Nov 11, 2026

Odyssey Therapeutics, Inc.

ODTX · US
Weakest Setup

Our calculation puts a fair price 43% below what the stock costs today.

Negative equity (buybacks among others)
Mixed vs. peers (2/5)
Fair value $11.46 · Strongly overvalued
Quality 34/100
Weak Growth (revenue YoY −33.5 %/yr in USD)
Negative free cash flow
Narrow moat 30/100 · thin data
Thin data
Estimate
Watch Odyssey Therapeutics, Inc. Common Stock for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$28.76 $15.56 Fair Value $11.46 May 2026 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 11, 2026.

How to read this chart

6‑month range $15.56 – $28.76 · fair‑value band $8.59 – $14.32 · the $20.00 price screens above the $11.46 fair value. As of Nov 11, 2026.

Follow Odyssey Therapeutics, Inc. Common Stock in your weekly email

Every Wednesday you see whether Odyssey Therapeutics, Inc. Common Stock is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Odyssey Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines for autoimmune and inflammatory diseases.

Show moreShow less

The company pipeline includes OD-001, an oral small molecule inhibitor of receptor-interacting protein kinase 2, which is in phase 2a trial for the treatment of ulcerative colitis; OD-002, an oral small molecule SLC15A4 inhibitor designed to block TLR7/8/9-mediated pathogenic inflammatory responses activation of interferon regulatory factor 5 (IRF5); OD-003, a protein therapeutic designed to agonize tumor necrosis factor receptor 2 selectively on Treg; a TSLP/IL-33 bispecific antagonist; an oral small molecule interleukin-1 receptor"associated kinase 4 scaffolding inhibitor; and a small molecule inhibitor of IRF5. The company was incorporated in 2021 and is headquartered in Boston, Massachusetts.

Stock analysis

Odyssey Therapeutics, Inc. (ODTX) currently trades at $20.00, while our estimate is $11.46, 43% below the price, so the stock looks overvalued today.

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $8.59 (bear) to $14.32 (bull), the price of $20.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 34/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is weak, negative or inconsistent.

Odyssey Therapeutics, Inc. Common Stock reported revenue of $3.0M in FY2025 versus $0 in FY2022. Reported net income was −$149M in FY2025.

Key figures

Market cap $920M Small · EPS (TTM) $−6.33 · Return on equity −85.5% · Return on assets (EBIT) −53.4% (4-year average) · Free cash flow −$131M.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 30 out of 100 (low confidence).

What moves the price

For context, the median of 10 Healthcare peers we cover trades at −7% fair-value upside, at −43%, ODTX screens richer than that median.

Fair Value

Bear $8.59 Fair Value $11.46 Bull $14.32
Price $20.00 · Downside -42.7%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 34/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 0
How much profit the company makes from its sales and capital
Quality Growth 36
Are margins and returns getting better?
Cashflow 8
Do the profits arrive as real cash?
Financial strength 38
Debt, balance sheet and risk of trouble
Investment 50
Does it invest with discipline instead of growing at any price?
Low Volatility 0
How calm the share price moves, does not count
Price momentum 47
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 46
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, no officer or director bought or sold shares on the open market.

  • BuyJames G CoulterFormer 10% Owner1,388,889 shares at $18.00$25.0MMay 11, 2026
  • BuyShelley ChuDirector11,111 shares at $18.00$199,998May 11, 2026
  • BuyNan (LN) LiDirector1,111,111 shares at $18.00$20.0MMay 11, 2026
  • SaleSimeon George10% owner1,780 shares at $18.00$32,040May 11, 2026
  • BuySimeon George10% owner555,555 shares at $18.00$10.0MMay 11, 2026
  • BuyDimension Capital II, L.P.Director1,111,111 shares at $18.00$20.0MMay 8, 2026
  • BuyJason HaasChief Financial Officer1,000 shares at $20.00$20,000May 8, 2026
  • BuyJeffrey M LeidenDirector5,000 shares at $20.00$100,000May 8, 2026

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue growth is weak, negative or inconsistent.
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

ODTX screens overvalued: fair value 43% below the price. Compare with Vertex Pharmaceuticals Incorporated →

Compare Odyssey Therapeutics, Inc. Common Stock with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 849 stocks

Beats the industry median on 2/5 measures
A mixed picture versus its industry peers.
Valuation
Quality Score 34 · Below median
Fair Value upside −42.7% · Bottom 25%
Profitability
Return on equity (12 months) Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.
Return on assets −55.1% · Bottom 25%
Operating margin (12 months) 0.0% · Above median
Growth and dividend
Revenue growth (quarter YoY) 0.0% · Above median
Balance sheet
Debt / equity Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Valuation Multiplesvs Biotechnology median · lower = cheaper

P/B Negative equity ⓘThe company's equity is below zero, for example after large share buybacks. A ratio to negative equity has no meaning, so we show no number here and do not rank it against the peer group.

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Regeneron Pharmaceuticals, Inc REGN $916.06 $1,275 +39% vs ODTX
Samsung Biologics Co 207940 1,468,000 KRW 1,661,000 KRW +13% vs ODTX
Vertex Pharmaceuticals Incorporated VRTX $547.89 $601.80 +10% vs ODTX
Genmab A/S GMAB kr 3,581 kr 3,880 +8% vs ODTX
argenx SE ARGX $971.55 $908.40 −7% vs ODTX
CSL Limited CSL A$201.68 A$181.40 −10% vs ODTX
Moderna, Inc MRNA $250.83 $158.70 −37% vs ODTX
BeOne Medicines AG 6160 HK$252.20 HK$152.80 −39% vs ODTX
Celltrion, Inc 068270 203,000 KRW 74,945 KRW −63% vs ODTX
Royalty Pharma plc RPRX $69.45 $19.01 −73% vs ODTX

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Odyssey Therapeutics, Inc. Common Stock: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "Odyssey Therapeutics, Inc. Common Stock Fair Value". https://www.fairvalue-calculator.com/stock/ODTX

Frequently asked questions

Is Odyssey Therapeutics, Inc. (ODTX) overvalued or undervalued?
As of Nov 11, 2026, our estimate of fair value is $11.46 versus a price of $20.00, about 43% lower (overvalued).
What is the fair value of ODTX?
Our estimate for Odyssey Therapeutics, Inc. is $11.46 (as of Nov 11, 2026), built from audited fundamentals. The current price: $20.00.
What is the quality score of ODTX?
Odyssey Therapeutics, Inc. has a Quality Score of 34/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Odyssey Therapeutics, Inc. (ODTX)?
Our calculated price target is the estimate of $11.46 (as of Nov 11, 2026). Cautious scenario $8.59, optimistic scenario $14.32. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the Odyssey Therapeutics, Inc. Common Stock stock forecast for 2026?
Our estimate puts fair value at $11.46, about 43% lower versus a price of $20.00 (overvalued). Cautious scenario $8.59, optimistic scenario $14.32. The calculation is refreshed regularly with new filings.
What is the intrinsic value of Odyssey Therapeutics, Inc. (ODTX)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Odyssey Therapeutics, Inc. it is $11.46 per share (as of Nov 11, 2026), against a price of $20.00.
Is Odyssey Therapeutics, Inc. Common Stock stock overvalued or undervalued in 2026?
As of Nov 11, 2026, ODTX trades above its calculated fair value: price $20.00, fair value $11.46, a gap of about −43% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of ODTX?
No. The price is what the market pays today ($20.00); the fair value is what the company's own numbers justify ($11.46). For Odyssey Therapeutics, Inc. the two are $8.54 per share apart. That gap is exactly why we show both numbers side by side.
How much is Odyssey Therapeutics, Inc. Common Stock worth?
The market values Odyssey Therapeutics, Inc. at about $920M (market capitalisation, as of Nov 11, 2026). Per share that is $20.00; our models calculate a fair value of $11.46 per share.
What do the bullish and bearish scenarios say about ODTX?
Our models span a range for Odyssey Therapeutics, Inc.: cautious scenario $8.59, base $11.46, optimistic $14.32 per share (as of Nov 11, 2026, price $20.00). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Odyssey Therapeutics, Inc. (ODTX)?
Balance-sheet figures for Odyssey Therapeutics, Inc. (as of Nov 11, 2026): negative equity, so no return on equity and no debt-to-equity ratio. They feed the Quality Score of 34/100, which measures business quality independently of the share price.
Which stocks are comparable to Odyssey Therapeutics, Inc. Common Stock?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Moderna, Inc, Regeneron Pharmaceuticals, Inc, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Odyssey Therapeutics, Inc. Common Stock stock attractive at the current price?
The data as of Nov 11, 2026: price $20.00, calculated fair value $11.46 (−43%), Quality Score 34/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. Odyssey Therapeutics, Inc. itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Odyssey Therapeutics, Inc. (ODTX)?
The closing price on Nov 10, 2026 was $20.00. Our estimate is $11.46, about 43% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Odyssey Therapeutics, Inc. Common Stock right now?
The price sits above even our optimistic bull case ($14.32). The favourable scenario is already priced in. Weak quality (34/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Key figures of Odyssey Therapeutics, Inc.

How large is the market capitalisation of Odyssey Therapeutics, Inc. (ODTX)?
The market capitalisation of Odyssey Therapeutics, Inc. is $920M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Odyssey Therapeutics, Inc. (ODTX)?
Earnings per share at Odyssey Therapeutics, Inc. are $−6.33. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Odyssey Therapeutics, Inc. (ODTX)?
The return on equity (ROE) of Odyssey Therapeutics, Inc. is −85.5% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Odyssey Therapeutics, Inc. (ODTX)?
On an EBIT basis the return on assets of Odyssey Therapeutics, Inc. is −53.4% (avg 4y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
How much free cash flow does Odyssey Therapeutics, Inc. (ODTX) generate?
The free cash flow of Odyssey Therapeutics, Inc. is −$131M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Odyssey Therapeutics, Inc. Common Stock in the live analysis

One click puts Odyssey Therapeutics, Inc. Common Stock on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.